Please assess the completion status of the following clinical trial:

Trial Title: Rilonacept (Arcalyst ®) in the Treatment of Subacromial Bursitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years of age or older and at a minimum have a recent history (more than 3 days worth) of shoulder pain with moderate to severe tenderness to palpation over the subacromial bursa.~Exclusion Criteria:~* Allergies to lidocaine, marcaine, or kenalog.~* Allergies to rilonacept~* Flare of active inflammatory arthritis (such as a flare of Rheumatoid Arthritis)~* Gout or Pseudogout attack of the shoulder with subacromial tenderness~* Active infection~* Actively receiving chemotherapy, radiation therapy, or anticipating surgery for neoplasia~* Active myocardial infarction~* Clinical and/or radiographic evidence of a fracture (clavicular, humeral, or other).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rilonacept (Type: ACTIVE_COMPARATOR): 160 mg of rilonacept will be injected in the subacromial bursa of participants in this arm.
- Corticosteroid (Type: PLACEBO_COMPARATOR): 80 mg (2 cc of 40 mg/mL) Kenalog intra-bursal once

Based on this trial design, predict the completion outcome and termination type (if applicable).